Details of the Drug Combination

General Information of Drug Combination (ID: DCSCXOD)

Drug Combination Name
MK-3207 Elesclomol
Indication
Disease Entry Status REF
Hepatoblastoma Investigative [1]
Component Drugs MK-3207   DM6OLGC Elesclomol   DMCE5DP
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HB3
Zero Interaction Potency (ZIP) Score: 4.548
Bliss Independence Score: 3.341
Loewe Additivity Score: 0.051
LHighest Single Agent (HSA) Score: 4.165

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-3207
Disease Entry ICD 11 Status REF
Migraine 8A80 Phase 2 [2]
MK-3207 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Calcitonin gene-related peptide receptor (CGRPR) TTY6O0Q CALRL_HUMAN Antagonist [4]
------------------------------------------------------------------------------------
Indication(s) of Elesclomol
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [3]

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT00712725) MK3207 for Treatment of Acute Migraines (3207-005). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT00522834) Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma. U.S. National Institutes of Health.
4 Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60.